Servier Acquires Symphogen A/S from Novo Holdings and Other Owners

Genmab A/S Acquires Merus N.V. via Tender Offer

December 12, 2025

Biotechnology

Genmab A/S, through its wholly owned purchaser Genmab Holding II B.V., completed a tender offer to acquire outstanding common shares of Merus N.V. for $97.00 per share and commenced a subsequent offering period. The acquisition adds Merus' lead late‑stage oncology asset petosemtamab to Genmab's portfolio, expanding its antibody therapeutics pipeline and expected to be accretive to EBITDA by 2029.

Genmab Acquires ProfoundBio for $1.8 Billion

April 3, 2024

Biotechnology

Genmab A/S will acquire clinical-stage biotech ProfoundBio, Inc. in an all-cash transaction valued at USD 1.8 billion to obtain worldwide rights to ProfoundBio's pipeline of antibody-drug conjugates (ADCs), including rinatabart sesutecan (Rina-S). The deal is intended to broaden and strengthen Genmab's oncology and ADC capabilities and is expected to close in the first half of 2024, subject to customary conditions.

Lonza Group AG Acquires Synaffix B.V.

June 1, 2023

Biotechnology

Lonza Group AG has acquired Synaffix B.V., a Netherlands-based biotech company that commercialises a clinical-stage antibody-drug conjugate (ADC) technology platform. The deal brings Synaffix's ADC bioconjugation technology into Lonza's integrated ADC development and manufacturing offering to accelerate discovery, development, scale-up and commercialization of ADCs.

Valerio Therapeutics Acquires Emglev Therapeutics

September 29, 2024

Biotechnology

Valerio Therapeutics S.A. completed the acquisition of Emglev Therapeutics on September 29, 2024, transferring Emglev's proprietary synthetic single-domain antibody (sdAb) platform into a newly formed Valerio subsidiary, Valour Bio. The deal was structured as a cash sale of shares combined with a contribution-in-kind (Emglev shares exchanged for Valour Bio shares), making Emglev shareholders shareholders of Valour Bio and positioning Valour Bio to advance sdAb discovery and development across oncology and inflammatory/autoimmune indications.

Merck & Co., Inc. Acquires VelosBio Inc.

November 5, 2020

Biotechnology

Merck & Co., Inc. will acquire all outstanding shares of clinical-stage biopharmaceutical company VelosBio for $2.75 billion in cash. The acquisition adds VelosBio's lead investigational antibody-drug conjugate VLS-101 and ROR1-directed pipeline assets to Merck's oncology portfolio and is expected to close by the end of 2020, subject to customary conditions.

ARCHIMED Acquires and Merges Symbio and Proinnovera to Form Symbio Proinnovera

November 17, 2023

Healthcare Services

ARCHIMED has acquired US-based Symbio and Germany-based Proinnovera in an all-equity deal and merged them to create Symbio Proinnovera, a specialized dermatology-focused CRO. The combined group will offer end-to-end dermatology consulting, formulation, testing and clinical research across North America and Europe, with founders rolling equity into the new platform and ARCHIMED-appointed operating partners joining the board to drive growth and further acquisitions.